Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravitreal Aflibercept for Type 1 Choroidal Neovascularization Assessed by OCT and OCT Angiography
KCT0007375Phase 4Active, not recruiting
- Sponsor
- Bayer
- Start
- May 2018
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 4 trial of aflibercept in age-related macular degeneration (AMD), sponsored by Bayer. Started May 2018; status: active, not recruiting.
02
Drugs
aflibercept
03
Conditions
age-related macular degeneration (AMD)
Beyond the preview
Go deeper on KCT0007375.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0007375.